These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 26526740)
1. Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors. Ravez S; Arsenlis S; Barczyk A; Dupont A; Frédérick R; Hesse S; Kirsch G; Depreux P; Goossens L Bioorg Med Chem; 2015 Nov; 23(22):7340-7. PubMed ID: 26526740 [TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives Containing Benzo[d]thiazole-2-yl Urea as c-Met Kinase Inhibitors. Lei H; Hu G; Wang Y; Han P; Liu Z; Zhao Y; Gong P Arch Pharm (Weinheim); 2016 Aug; 349(8):651-61. PubMed ID: 27283017 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel 3-pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives as potent receptor tyrosine kinase inhibitors. Ding L; Tang F; Huang W; Jin Q; Shen H; Wei P Bioorg Med Chem Lett; 2013 Oct; 23(20):5630-3. PubMed ID: 23999040 [TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives. El-Gamal MI; Khan MA; Tarazi H; Abdel-Maksoud MS; Gamal El-Din MM; Yoo KH; Oh CH Eur J Med Chem; 2017 Feb; 127():413-423. PubMed ID: 28088086 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents. Qi H; Chen L; Liu B; Wang X; Long L; Liu D Bioorg Med Chem Lett; 2014 Feb; 24(4):1108-10. PubMed ID: 24456902 [TBL] [Abstract][Full Text] [Related]
6. Structure-based de novo design and identification of D816V mutant-selective c-KIT inhibitors. Park H; Lee S; Lee S; Hong S Org Biomol Chem; 2014 Jul; 12(26):4644-55. PubMed ID: 24853767 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors. Yin Y; Lin L; Ruiz C; Khan S; Cameron MD; Grant W; Pocas J; Eid N; Park H; Schröter T; Lograsso PV; Feng Y J Med Chem; 2013 May; 56(9):3568-81. PubMed ID: 23570561 [TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor. Raeppel SL; Raeppel F; Therrien E Bioorg Med Chem Lett; 2015 Jun; 25(12):2527-31. PubMed ID: 25953155 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase. Shi ZH; Liu FT; Tian HZ; Zhang YM; Li NG; Lu T Bioorg Med Chem; 2018 Sep; 26(16):4735-4744. PubMed ID: 30121211 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors. af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129 [TBL] [Abstract][Full Text] [Related]
11. Discovery of 8-Amino-Substituted 2-Phenyl-2,7-Naphthyridinone Derivatives as New c-Kit/VEGFR-2 Kinase Inhibitors. Sun H; Zhuo L; Dong H; Huang W; She N Molecules; 2019 Dec; 24(24):. PubMed ID: 31817456 [TBL] [Abstract][Full Text] [Related]
12. Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants. Wu TS; Lin WH; Tsai HJ; Hsueh CC; Hsu T; Wang PC; Lin HY; Peng YH; Lu CT; Lee LC; Tu CH; Kung FC; Shiao HY; Yeh TK; Song JS; Chang JY; Su YC; Chen LT; Chen CT; Jiaang WT; Wu SY J Med Chem; 2019 Apr; 62(8):3940-3957. PubMed ID: 30968693 [TBL] [Abstract][Full Text] [Related]
13. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Gandin V; Ferrarese A; Dalla Via M; Marzano C; Chilin A; Marzaro G Sci Rep; 2015 Nov; 5():16750. PubMed ID: 26568452 [TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors. Tang Q; Zhang G; Du X; Zhu W; Li R; Lin H; Li P; Cheng M; Gong P; Zhao Y Bioorg Med Chem; 2014 Feb; 22(4):1236-49. PubMed ID: 24485123 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies. Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298 [TBL] [Abstract][Full Text] [Related]
16. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors. Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors. Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748 [TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors. Raeppel SL; Therrien E; Raeppel F Bioorg Med Chem Lett; 2015 Sep; 25(17):3706-10. PubMed ID: 26112445 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases. Thompson AM; Delaney AM; Hamby JM; Schroeder MC; Spoon TA; Crean SM; Showalter HD; Denny WA J Med Chem; 2005 Jul; 48(14):4628-53. PubMed ID: 16000000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]